Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

NCT05737953 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-02-11

No results posted yet for this study

Summary

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are:

Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy.

Participants will Provide post-operative cyst fluid specimens.

Conditions

  • Pancreatic Neoplasms
  • DNA Methylation
  • Proteome

Interventions

DIAGNOSTIC_TEST

cfDNA methylation sequencing and proteome analysis

Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples

Sponsors & Collaborators

  • Oriental Hepatobiliary Surgery Hospital Affiliated to Naval Military Medical University

    collaborator UNKNOWN
  • Zhejiang University

    collaborator OTHER
  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER
  • West China Hospital

    collaborator OTHER
  • LanZhou University

    collaborator OTHER
  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER
  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • First Hospital of China Medical University

    collaborator OTHER
  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER
  • The Second Affiliated Hospital of Baotou Medical College

    collaborator OTHER
  • Shandong Province Third hospital

    collaborator OTHER
  • Zhaoshen Li

    lead OTHER

Principal Investigators

  • Shiyu Li · Changhai Hospital

  • Chengye Pan · Changhai Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737953 on ClinicalTrials.gov